General Information
|
|
Product
|
MAP3K8 Peptide
|
Description
|
Antigenic Blocking Peptide Mitogen-activated protein kinase kinase kinase 8
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
Peptide Description
|
Synthetic peptide taken within amino acid region 360-467 on human MAP3K8 protein.
|
Accession #
|
GenBank: AAI13567.1
|
Physical Properties
|
|
Quantity
|
250 µg
|
Volume
|
100 µl
|
Form
|
Antigenic Blocking Peptide
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
Protein
|
Uniprot #
|
P41279
|
Overview
|
Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
|
Molecular Function
|
Kinase, Serine/threonine-protein kinase, Transferase
|
Subcellular Location
|
Cytoplasm
|
Expression
|
Expressed in several normal tissues and human tumor-derived cell lines.
|
Structure
|
Forms a ternary complex with NFKB1/p105 and TNIP2. Interacts with NFKB1; the interaction increases the stability of MAP3K8 but inhibits its MEK phosphorylation activity, whereas loss of interaction following LPS stimulation leads to its degradation. Interacts with CD40 and TRAF6; the interaction is required for ERK activation. Interacts with KRS2; the interaction inhibits ERK and NF-kappa-B activation.
|
Alternative Nomenclature
|
c COT antibody
Cancer Osaka thyroid oncogene antibody
COT antibody
COT proto oncogene serine/threonine protein kinase antibody
EST antibody
ESTF antibody
Ewing sarcoma transformant antibody
FLJ10486 antibody
MEKK8 antibody
Mitogen activated protein kinase kinase kinase 8 antibody
Proto oncogene cCot antibody
Serine/threonine-protein kinase cot antibody
TPL 2 antibody
Tumor progression locus 2 antibody
|
|
|